Relmada Therapeutics, Inc.
- RLMD
- NASDAQ
- Biotechnology
- Cancer Drug Development
- Bladder Cancer Therapy
- Clinical-Stage Biotech
$3.16
Today +1.94%Quote Oct 19, 2026, 08:00 PM UTC
−23.30%over the last month
Max drawdown −26.9%From 1-month high −25.5%3 months −40.4%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Relmada Therapeutics
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
17
Founded
2004
Market value
$337.1M
Quote Oct 19
Analyst target
$12.00
+279.7% from here
Floor
$2.93
7.3% below price
Resistance
$3.24
2.5% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about RLMDPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free